Cancer Cell
Cancer Cell is Cell Press's dedicated cancer journal, publishing mechanism-rich papers on tumour biology, the microenvironment, resistance and biomarkers, plus the CPTAC proteogenomic atlases.
Cancer Cell appears monthly and publishes integrative multi-omic tumour studies (CPTAC proteogenomics, TCGA subtype papers), mechanisms of drug resistance, tumour-immune interactions and translational biomarker work that often accompanies clinical trials. Elsevier hybrid model.
Leukaemia researcher who found that AML stem cells depend on mitochondrial proteases and metabolism.
RAS biologist who founded Onyx Pharmaceuticals and led the NCI's national effort to drug RAS.
Discovered the JAK2 mutation behind most myeloproliferative neoplasms and defined the genetics of clonal haematopoiesis.
Leads China's largest cancer centre and has run the Chinese phase 3 trials that brought PD-1 antibodies into GI cancer.
Shaomeng Wang is the medicinal chemist behind some of the first clinical MDM2 inhibitors and PROTAC degraders.
Co-architect of the Fudan TNBC subtypes and the metabolic and immune atlases that guide subtype-specific treatment.
Leads the world's highest-volume breast cancer surgical unit and the FUTURE trial that treats triple-negative breast cancer by molecular subtype.